病毒学
维罗细胞
接种疫苗
2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
中和抗体
信使核糖核酸
抗体
病毒
冠状病毒
生物
医学
免疫学
基因
传染病(医学专业)
病理
疾病
生物化学
作者
Huarong Hong,Kwang Sung Kim,Shin Ae Park,Min Jeong Chun,Eun Young Hong,Seok Won Chung,Hyun Jong Kim,Byeong Gyu Shin,Yang Je Cho,A. Braka,Jayaraman Thangappan,Sang-Min Jang,Sangwook Wu,Seok-Hyun Kim
标识
DOI:10.1101/2021.03.22.436375
摘要
Abstract In addition to the traditional method of vaccine development, the mRNA coronavirus vaccine, which is attractive as a challenging vaccination, recently opened a new era in vaccinology. Here we describe the EG-COVID which is a novel liposome-based mRNA candidate vaccine that encodes the spike (S) protein of SARS-CoV-2 with 2P-3Q substitution in European variant. We developed the mRNA vaccine platform that can be lyophilized using liposome-based technology. Intramuscular injection of the EG-COVID elicited robust humoral and cellular immune response to SARS-CoV-2. Furthermore, sera obtained from mice successfully inhibited SARS-CoV-2 viral infection into Vero cells. We developed EG-COVID and found it to be effective based on in vitro data, and we plan to initiate a clinical trial soon. Since EG-COVID is a lyophilized mRNA vaccine that is convenient for transportation and storage, accessibility to vaccines will be significantly improved.
科研通智能强力驱动
Strongly Powered by AbleSci AI